MANJUSHA GAGLANI to Outpatients
This is a "connection" page, showing publications MANJUSHA GAGLANI has written about Outpatients.
Connection Strength
1.420
-
Effectiveness of the influenza vaccine for preventing laboratory-confirmed influenza infections in outpatient immunocompromised adults, 2017-2018. Hum Vaccin Immunother. 2024 Dec 31; 20(1):2354013.
Score: 0.201
-
Late-Season Influenza Vaccine Effectiveness Against Medically Attended Outpatient Illness, United States, December 2022-April 2023. Influenza Other Respir Viruses. 2024 06; 18(6):e13342.
Score: 0.200
-
Effectiveness of two and three mRNA COVID-19 vaccine doses against Omicron- and Delta-Related outpatient illness among adults, October 2021-February 2022. Influenza Other Respir Viruses. 2022 11; 16(6):975-985.
Score: 0.176
-
Influenza vaccine effectiveness among outpatients in the US Influenza Vaccine Effectiveness Network by study site 2011-2016. Influenza Other Respir Viruses. 2020 07; 14(4):380-390.
Score: 0.150
-
Hospitalization following outpatient medical care for influenza: US influenza vaccine effectiveness network, 2011-12-2015-16. Influenza Other Respir Viruses. 2019 03; 13(2):133-137.
Score: 0.137
-
Use of influenza antiviral medications among outpatients at high risk for influenza-associated complications during the 2013-2014 influenza season. Clin Infect Dis. 2015 Jun 01; 60(11):1677-80.
Score: 0.105
-
Anti-SARS-CoV-2 Antibody Levels Associated With COVID-19 Protection in Outpatients Tested for SARS-CoV-2, US Flu Vaccine Effectiveness Network, October 2021-June 2022. J Infect Dis. 2024 Jul 25; 230(1):45-54.
Score: 0.050
-
Post-recovery health domain scores among outpatients by SARS-CoV-2 testing status during the pre-Delta period. BMC Infect Dis. 2024 Mar 08; 24(1):300.
Score: 0.049
-
Prior SARS-CoV-2 infection and COVID-19 vaccine effectiveness against outpatient illness during widespread circulation of SARS-CoV-2 Omicron variant, US Flu VE network. Influenza Other Respir Viruses. 2023 05; 17(5):e13143.
Score: 0.046
-
Vaccine-associated attenuation of subjective severity among outpatients with influenza. Vaccine. 2022 07 30; 40(32):4322-4327.
Score: 0.044
-
Messenger RNA Vaccine Effectiveness Against Coronavirus Disease 2019 Among Symptomatic Outpatients Aged =16 Years in the United States, February-May 2021. J Infect Dis. 2021 11 22; 224(10):1694-1698.
Score: 0.042
-
Influenza Vaccine Effectiveness in Inpatient and Outpatient Settings in the United States, 2015-2018. Clin Infect Dis. 2021 08 02; 73(3):386-392.
Score: 0.041
-
Influenza vaccination coverage among persons seeking outpatient medical care for acute respiratory illness in five states in the United States, 2011-2012 through 2018-2019. Vaccine. 2021 03 19; 39(12):1788-1796.
Score: 0.040
-
Relative effectiveness of high dose versus standard dose influenza vaccines in older adult outpatients over four seasons, 2015-16 to 2018-19. Vaccine. 2020 09 29; 38(42):6562-6569.
Score: 0.038
-
Influenza Vaccine Effectiveness in the United States During the 2016-2017 Season. Clin Infect Dis. 2019 05 17; 68(11):1798-1806.
Score: 0.035
-
Outpatient Antibiotic Prescribing for Acute Respiratory Infections During Influenza Seasons. JAMA Netw Open. 2018 06 01; 1(2):e180243.
Score: 0.033
-
Influenza Antiviral Prescribing for Outpatients With an Acute Respiratory Illness and at High Risk for Influenza-Associated Complications During 5 Influenza Seasons-United States, 2011-2016. Clin Infect Dis. 2018 03 19; 66(7):1035-1041.
Score: 0.033